Clinical Benefit of EGFR-TKIs Plus Radiotherapy for Treating EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer

被引：0
|
作者：
Li, T. [1 ]
Wang, R. [1 ]
Lv, J. [1 ]
Sun, C. [2 ]
Shi, Q. [3 ]
机构：
[1] Univ Elect Sci & Technol China, Dept Radiat Oncol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China
[2] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Sichuan, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.1354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3187
引用
收藏
页码：E516 / E517
页数：2
相关论文
共 50 条
  • [1] Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer.
    Wang, Ran Lin
    Li, Tao
    Lv, Jiahua
    Sun, Chang
    Shi, Qiuling
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
    Hu, Chunhong
    Wu, Sixuan
    Deng, Renfang
    Wu, Yuanqiang
    Pan, Yue
    Shu, Long
    Wu, Fang
    [J]. CANCER MEDICINE, 2023, 12 (01): : 266 - 273
  • [3] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [4] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Sequist, L. V.
    Soria, J-C
    Goldman, J. W.
    Wakelee, H. A.
    Gadgeel, S. M.
    Varga, A.
    Papadimitrakopoulou, V.
    Solomon, B. J.
    Oxnard, G. R.
    Dziadziuszko, R.
    Aisner, D. L.
    Doebele, R. C.
    Galasso, C.
    Garon, E. B.
    Heist, R. S.
    Logan, J.
    Neal, J. W.
    Mendenhall, M. A.
    Nichols, S.
    Piotrowska, Z.
    Wozniak, A. J.
    Raponi, M.
    Karlovich, C. A.
    Jaw-Tsai, S.
    Isaacson, J.
    Despain, D.
    Matheny, S. L.
    Rolfe, L.
    Allen, A. R.
    Camidge, D. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1700 - 1709
  • [5] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    He, Yong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (06): : 578 - 578
  • [6] Case report: Rechallenge with EGFR-TKIs after immunotherapy in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis
    Qian, Chunfa
    Zhang, Yuhai
    Cheng, Wanwan
    Zhang, Qingchao
    Li, Mengzhen
    Fang, Shencun
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Planchard, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1780 - 1782
  • [8] Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer
    Ito, Takashi
    Nagashima, Hiromi
    Akiyama, Masachika
    Utsumi, Yu
    Sato, Hideomi
    Chiba, Shinji
    Sugai, Mayu
    Ube, Kenji
    Mori, Yoshiaki
    Watanabe, Kana
    Fukuhara, Tatsuro
    Maemondo, Makoto
    [J]. THORACIC CANCER, 2022, 13 (03) : 386 - 393
  • [9] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [10] Future prospects of EGFR-TKIs and surgery for non-small-cell lung cancer
    Nagano, Tatsuya
    Tachihara, Motoko
    Tanaka, Yugo
    [J]. JOURNAL OF THORACIC DISEASE, 2022, 14 (04) : 809 - 811
12345